We Are Ananda Pharma
We're Focused on the Research and Development of CBD-based Therapies
Ananda is developing a range of cannabinoid-based medicines targeting the treatment of complex, chronic inflammatory pain conditions.
Backed By Leading Global Companies
The Opportunity For Cannabinoid Medicines
The Global Anti-Inflammatory Drugs Market Is Projected To Reach $118.4bn By 2027
We’re Developing NHS approved and MHRA licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure
Our Portfolio
Discover Our Clinical Trials
Our Approach
Transforming Lives Through Cannabinoid Medicines
We believe that cannabidiol, with its multiple molecular and cellular mechanisms of action has the potential to become a crucial element in the treatment plans for many complex conditions, especially in chronic pain and inflammatory indications.
The Ananda Pharma Board Of Directors